SCHEMBL4572247

SCHEMBL4572247

Nc1cccc(S(=O)(=O)Nc2cccc(C(=O)N[C@@H](CCCNC(N)N)C(=O)O)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NRP1 O14786 1/20 0.50
POLB P06746 2/20 0.46
HTR6 P50406 1/20 0.44
PFKFB3 Q16875 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
GAA P10253 1/20 0.42
ATIC P31939 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
THRB P10828 1/20 0.41
MAPT P10636 2/20 0.41
PKM P14618 2/20 0.41
EGFR P00533 1/20 0.39
FGFR1 P11362 1/20 0.39
KDR P35968 1/20 0.39
CA2 P00918 1/20 0.39
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4572260 0.92 ATIC (0.46) NRP1POLBHTR6ATICMEN1
SCHEMBL4569803 0.87 NRP1 (0.51) NRP1POLBHTR6PFKFB3HDAC2
SCHEMBL4572257 0.84 DDX3X (0.47) HDAC2HDAC8HDAC6
SCHEMBL4572300 0.83 NRP1 (0.54) NRP1POLBGAAMEN1KMT2A
SCHEMBL4572250 0.82 NRP1 (0.74) NRP1
SCHEMBL4572249 0.80 NRP1 (0.53) NRP1POLBHDAC2HDAC8HDAC6
SCHEMBL3696198 0.79 NRP1 (0.45) NRP1POLBHTR6ATICMEN1
SCHEMBL4572273 0.77 NRP1 (0.48) NRP1
SCHEMBL10067889 0.77 C3AR1 (0.47) NRP1HTR6ATICCA2
SCHEMBL4572280 0.75 NRP1 (0.58) NRP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120269864-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2012-10-25 US disclosed
US-8227606-B2 Arginine derivatives with NP-1 antagonistic activity ARK THERAPEUTICS, LTD. (GB) 2012-07-24 US disclosed
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY GB06/019611.7 THERAPIES LIMITED (GB) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120269864-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 NRP1 145/4885POLB 4685/4885HTR6 2001/4885
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY NPFFR1, NPR1, ARG1 NRP1 145/4885POLB 4685/4885HTR6 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.